相似文献
1
The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.
Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):41B-55B. doi: 10.1016/s0828-282x(06)70986-2.
2
Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs.
J Am Coll Cardiol. 2002 Feb 20;39(4):732-8. doi: 10.1016/s0735-1097(01)01797-1.
3
Life and Death Partners in Post-PCI Restenosis: Apoptosis, Autophagy, and The Cross-talk Between Them.
Curr Drug Targets. 2018;19(9):1003-1008. doi: 10.2174/1389450117666160625072521.
4
Pathophysiology of coronary artery restenosis.
Rev Cardiovasc Med. 2002;3 Suppl 5:S4-9.
5
A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
EuroIntervention. 2011 May;7 Suppl K:K93-9. doi: 10.4244/EIJV7SKA16.
6
Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
JACC Cardiovasc Interv. 2009 Apr;2(4):300-2. doi: 10.1016/j.jcin.2009.01.004.
7
Interference of IP-10 expression inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in carotid artery: a new insight in the prevention of restenosis.
Cell Biochem Biophys. 2012 Jan;62(1):125-35. doi: 10.1007/s12013-011-9270-9.
8
EGR-1 decoy ODNs inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of balloon-injured arteries in rat.
Life Sci. 2010 Feb 13;86(7-8):234-43. doi: 10.1016/j.lfs.2009.12.005. Epub 2009 Dec 16.
9
Drug-eluting stent: a review and update.
Vasc Health Risk Manag. 2005;1(4):263-76. doi: 10.2147/vhrm.2005.1.4.263.
10
Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
Eur J Pharmacol. 2007 Sep 10;570(1-3):125-34. doi: 10.1016/j.ejphar.2007.05.050. Epub 2007 Jun 9.
引用本文的文献
1
Shared genetic architecture between neuroticism, coronary artery disease and cardiovascular risk factors.
Transl Psychiatry. 2021 Jun 17;11(1):368. doi: 10.1038/s41398-021-01466-9.
2
The COP9 signalosome and vascular function: intriguing possibilities?
Am J Cardiovasc Dis. 2015 Mar 20;5(1):33-52. eCollection 2015.
3
Arterial territory-specific phosphorylated retinoblastoma protein species and CDK2 promote differences in the vascular smooth muscle cell response to mitogens.
Cell Cycle. 2014;13(2):315-23. doi: 10.4161/cc.27056. Epub 2013 Nov 12.
4
Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2.
J Huazhong Univ Sci Technolog Med Sci. 2012 Feb;32(1):31-35. doi: 10.1007/s11596-012-0005-y. Epub 2012 Jan 27.
5
Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats.
Respir Res. 2010 Dec 24;11(1):182. doi: 10.1186/1465-9921-11-182.
本文引用的文献
1
First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study.
Cardiovasc Revasc Med. 2007 Oct-Dec;8(4):230-5. doi: 10.1016/j.carrev.2007.04.002.
2
Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
J Am Coll Cardiol. 2004 Oct 6;44(7):1386-92. doi: 10.1016/j.jacc.2004.06.069.
3
Preclinical restenosis models and drug-eluting stents: still important, still much to learn.
J Am Coll Cardiol. 2004 Oct 6;44(7):1373-85. doi: 10.1016/j.jacc.2004.04.060.
4
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
J Am Coll Cardiol. 2004 Oct 6;44(7):1363-7. doi: 10.1016/j.jacc.2004.03.084.
5
Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.
Cardiovasc Res. 2004 Oct 1;64(1):165-71. doi: 10.1016/j.cardiores.2004.06.013.
6
Drug-eluting stents: the end of restenosis?
Ann Acad Med Singap. 2004 Jul;33(4):423-31.
7
Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions.
J Am Coll Cardiol. 2004 Aug 18;44(4):733-9. doi: 10.1016/j.jacc.2004.04.048.
8
Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
Circulation. 2004 Aug 17;110(7):790-5. doi: 10.1161/01.CIR.0000138935.17503.35. Epub 2004 Aug 9.
9
Everolimus for stent-based intracoronary applications.
Rev Cardiovasc Med. 2004;5 Suppl 2:S3-8.
10
Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
FASEB J. 2004 Aug;18(11):1285-7. doi: 10.1096/fj.04-1646fje. Epub 2004 Jun 4.
Zotero 插件